{"id":"https://openalex.org/W4362544928","doi":"https://doi.org/10.1158/1535-7163.c.6539497","title":"Data from Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer","display_name":"Data from Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4362544928","doi":"https://doi.org/10.1158/1535-7163.c.6539497"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.c.6539497","doi":"https://doi.org/10.1158/1535-7163.c.6539497","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.c.6539497","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1535-7163.c.6539497","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5028010756","display_name":"Neil A. O\u2019Brien","orcid":"https://orcid.org/0000-0001-7408-1091","observed_orcids":["https://orcid.org/0000-0001-7408-1091"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Neil O'Brien","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045387212","display_name":"Dylan F. Conklin","orcid":"https://orcid.org/0000-0003-4708-0071","observed_orcids":["https://orcid.org/0000-0003-4708-0071"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dylan Conklin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109124374","display_name":"Richard Paul Beckmann","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Richard Beckmann","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013404372","display_name":"Tong Luo","orcid":"https://orcid.org/0000-0001-5382-7448","observed_orcids":["https://orcid.org/0000-0001-5382-7448"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tong Luo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Kevin Chau","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kevin Chau","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114250110","display_name":"Josh Thomas","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Josh Thomas","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002650661","display_name":"Ann Mc Nulty","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ann Mc Nulty","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027668278","display_name":"Christophe C. Marchal","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christophe Marchal","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054528392","display_name":"Ondrej Kalous","orcid":"https://orcid.org/0000-0002-3821-6603","observed_orcids":["https://orcid.org/0000-0002-3821-6603"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ondrej Kalous","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045874340","display_name":"Erika von Euw","orcid":"https://orcid.org/0000-0002-3201-3311","observed_orcids":["https://orcid.org/0000-0002-3201-3311"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Erika von Euw","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068059897","display_name":"Sara Alsterlind Hurvitz","orcid":"https://orcid.org/0000-0001-7808-7191","observed_orcids":["https://orcid.org/0000-0001-7808-7191"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sara Hurvitz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012002797","display_name":"Colleen M. Mockbee","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Colleen Mockbee","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5015491002","display_name":"Dennis J. Slamon","orcid":"https://orcid.org/0000-0002-6330-498X","observed_orcids":["https://orcid.org/0000-0002-6330-498X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dennis J. Slamon","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/abemaciclib","display_name":"abemaciclib","score":1.0},{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.9679999947547913},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.8420000076293945},{"id":"https://openalex.org/keywords/estrogen-receptor-positive-breast-cancer","display_name":"estrogen receptor-positive breast cancer","score":0.7580000162124634},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.9629999995231628},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":1.0},{"id":"https://openalex.org/keywords/cyclin-d1","display_name":"cyclin D1","score":0.5450000166893005},{"id":"https://openalex.org/keywords/pharmacodynamic-markers","display_name":"pharmacodynamic biomarkers","score":0.8679999709129333},{"id":"https://openalex.org/keywords/antimitotic-agents","display_name":"antimitotic agents","score":0.8209999799728394},{"id":"https://openalex.org/keywords/her2-targeted-therapy","display_name":"HER2-targeted therapy","score":0.8849999904632568},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8880000114440918},{"id":"https://openalex.org/keywords/drug-sensitivity","display_name":"drug sensitivity","score":0.44999998807907104},{"id":"https://openalex.org/keywords/xenograft-models","display_name":"xenograft models","score":0.718999981880188}],"concepts":[{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6360094547271729},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5732146501541138},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5509872436523438},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5281231999397278},{"id":"https://openalex.org/C2779744173","wikidata":"https://www.wikidata.org/wiki/Q15269707","display_name":"Palbociclib","level":5,"score":0.5100272297859192},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4573809802532196},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.35707414150238037},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3291255235671997},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.24210619926452637},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.15662723779678345},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1535-7163.c.6539497","doi":"https://doi.org/10.1158/1535-7163.c.6539497","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.c.6539497","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1535-7163.c.6539497.v1","doi":"https://doi.org/10.1158/1535-7163.c.6539497.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.c.6539497.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1535-7163.c.6539497","doi":"https://doi.org/10.1158/1535-7163.c.6539497","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.c.6539497","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2792066790","https://openalex.org/W2500433718","https://openalex.org/W3169821311","https://openalex.org/W4298742720","https://openalex.org/W2310088929","https://openalex.org/W2986010660","https://openalex.org/W3005929774","https://openalex.org/W4229063635","https://openalex.org/W2553488599","https://openalex.org/W4283786358"],"abstract_inverted_index":{"Abstract":[0],"The":[1,204],"cyclinD:CDK4/6:Rb":[2,229],"axis":[3],"is":[4],"dysregulated":[5],"in":[6,23,30,33,70,105,115,143,146,197,199,246],"a":[7,19,52,78,159,185,219,243],"variety":[8],"of":[9,46,54,80,99,153,161,176,188,192,218,222,237],"human":[10,200],"cancers.":[11],"Targeting":[12],"this":[13,28],"pathway":[14],"has":[15],"proven":[16],"to":[17,41,62,94,117,178,208,210],"be":[18,95,214],"successful":[20],"therapeutic":[21],"approach":[22],"ER+":[24],"breast":[25,36,56,82,201],"cancer.":[26],"In":[27,119],"study,":[29],"vitro":[31,144],"and":[32,66,74,145,171,250],"vivo":[34],"preclinical":[35,190],"cancer":[37,57,83,202],"models":[38],"were":[39,91,103],"used":[40,194],"investigate":[42],"the":[43,47,71,151,189,234],"expanded":[44],"use":[45],"CDK4/6":[48,134],"inhibitor,":[49],"abemaciclib.":[50,118,179],"Using":[51],"panel":[53],"44":[55],"cell":[58,85],"lines,":[59],"differential":[60],"sensitivity":[61],"abemaciclib":[63,121,137,238],"was":[64,67],"observed":[65,104],"seen":[68],"predominately":[69],"luminal":[72],"ER+/HER2\u2212":[73],"ER+/HER2+":[75,107],"subtypes.":[76],"However,":[77],"subset":[79],"triple-negative":[81],"(TNBC)":[84],"lines":[86],"with":[87,123,136,139,167,225],"intact":[88],"Rb":[89],"signaling":[90],"also":[92],"found":[93],"responsive.":[96],"Equivalent":[97],"levels":[98],"tumor":[100],"growth":[101,168],"inhibition":[102,135],"ER+/HER2\u2212,":[106,248],"as":[108,110,239,242],"well":[109],"biomarker":[111],"selected":[112,247],"TNBC":[113],"xenografts":[114],"response":[116,170,177],"addition,":[120],"combined":[122,138],"hormonal":[124],"blockade":[125],"and/or":[126],"HER2-targeted":[127],"therapy":[128],"induced":[129],"significantly":[130],"improved":[131],"antitumor":[132],"activity.":[133],"antimitotic":[140],"agents,":[141],"both":[142],"vivo,":[147],"did":[148],"not":[149],"antagonize":[150],"effect":[152],"either":[154],"agent.":[155],"Finally,":[156],"we":[157],"identified":[158,215],"set":[160,221],"Rb/E2F-regulated":[162],"genes":[163],"that":[164],"consistently":[165],"track":[166],"inhibitory":[169],"constitute":[172],"potential":[173],"pharmacodynamic":[174],"biomarkers":[175,223],"Taken":[180],"together,":[181],"these":[182],"data":[183,232],"represent":[184],"comprehensive":[186],"analysis":[187],"activity":[191],"abemaciclib,":[193],"alone":[195],"or":[196,241],"combination,":[198],"models.":[203],"subtypes":[205],"most":[206],"likely":[207],"respond":[209],"abemaciclib-based":[211],"therapies":[212],"can":[213],"by":[216],"measurement":[217],"specific":[220],"associated":[224],"increased":[226],"dependency":[227],"on":[228],"signaling.":[230],"These":[231],"support":[233],"clinical":[235],"development":[236],"monotherapy":[240],"combination":[244],"partner":[245],"HER2+/ER+,":[249],"TNBCs.":[251],"Mol":[252],"Cancer":[253],"Ther;":[254],"17(5);":[255],"897\u2013907.":[256],"\u00a92018":[257],"AACR.":[258]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-06T00:00:00"}